ArticleBMC psychiatry2025
Decreased serum VEGF levels and their negative correlation with cognitive function in patients with major depressive disorder: a case-control study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCognitive impairment in individuals with Major Depressive Disorder (MDD) may have an association with the levels of Vascular Endothelial Growth Factor (VEGF). However, the relationship between peripheral VEGF levels and cognitive function in MDD patients remains unclear and has not been thoroughly investigated in a clinical setting.
methodsIn this case-control study, we recruited 60 patients diagnosed with MDD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria (33 males and 27 females, mean age 41.17 ± 13.32 years) and 60 healthy controls (28 males and 32 females, mean age 37.20 ± 11.93 years). Serum VEGF levels were measured using an ELISA kit, and cognitive performance was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Group differences were analyzed using analysis of variance (ANOVA)/analysis of covariance (ANCOVA), and associations were assessed using Pearson's correlation. This study was approved by the Institutional Review Board of Suzhou Guangji Hospital.
resultsFollowing adjustment for variables such as gender, age, BMI, and other potential confounding factors, it was observed that the serum VEGF levels in individuals with depression were significantly reduced compared to those in the corresponding healthy control group (F = 4.55, p = 0.04). Within the depressive patient cohort, serum VEGF levels negatively correlated with attention scores (r=-0.32, p = 0.01) and RBANS total scores (r=-0.28, p = 0.03). Conversely, no such correlations were observed in the healthy control group (attention scores: r = 0.19, p = 0.15; RBANS total scores: r=-0.03, p = 0.82).
conclusionsOur study suggests that reduced serum VEGF levels may contribute to cognitive impairment in MDD, warranting further investigation into its potential role as a biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.